Background: Tapentadol, a centrally acting oral analgesic, activates µ-opioid receptor and inhibits norepinephrine reuptake. Given that glutamate plays a crucial role in mediating pain, this study investigated the influence of tapentadol on spontaneous glutamatergic synaptic transmission and evoked neuronal excitability in rat hippocampal CA3 pyramidal neurons, which has been suggested to be involved in nociceptive perception. Methods: We used electrophysiological technique to determine the effect of tapentadol on spontaneous excitatory postsynaptic currents (sEPSC), glutamate-activated currents, and neuronal excitability in CA3 pyramidal neurons in rat hippocampal slices. We also used isolated nerve terminals (synaptosomes) prepared from the rat hippocampus to examine the effect of tapentadol on glutamate release. Results: Whole-cell patch clamp recordings revealed that tapentadol effectively decreased the frequencies of sEPSCs and miniature EPSCs (mEPSCs) without changing their amplitudes in hippocampal CA3 pyramidal neurons. However, glutamate-evoked inward currents were not affected by tapentadol. Further, tapentadol decreased 4-aminopyridine-induced glutamate release from hippocampal synaptosomes, and this effect was prevented by chelating the extracellular Ca2+ ions and blocking the N- and P/Q-type Ca2+ channels. In addition, burst firing induced by 4-aminopyridine and tonic repetitive firing induced by depolarizing pulses were attenuated by tapentadol. Conclusions: We conclude that tapentadol inhibits glutamatergic synaptic transmission, without modifying postsynaptic receptor sensitivity, and that this decline of excitation consequently suppresses neuronal hyperexcitability in the hippocampal CA3 area.

Keywords:
Tapentadol, Excitatory synaptic activity, Glutamate release, Neuronal excitability, Hippocampal slices
1.
van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies.
Pain
. 2014 Apr;155(4):654–62.
2.
O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines.
Am J Med
. 2009 Oct;122(10 Suppl):S22–32.
3.
Osikowicz M, Mika J, Przewlocka B. The glutamatergic system as a target for neuropathic pain relief.
Exp Physiol
. 2013 Feb;98(2):372–84.
4.
Baker K. Recent advances in the neurophysiology of chronic pain.
Emerg Med Australas
. 2005 Feb;17(1):65–72.
5.
Gerdle B, Larsson B, Forsberg F, Ghafouri N, Karlsson L, Stensson N, et al. Chronic widespread pain: increased glutamate and lactate concentrations in the trapezius muscle and plasma.
Clin J Pain
. 2014 May;30(5):409–20.
6.
Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH. Cerebrospinal fluid glutamate levels in chronic migraine.
Cephalalgia
. 2004 Sep;24(9):735–9.
7.
Lambert DG. Mechanisms of action of general anaesthetic drugs.
Anaesth Intensive Care Med
. 2011;12(4):141–3.
8.
Block F, Habermeyer B. [Glutamate antagonists for treatment of neuropathic pain].
Schmerz
. 2003 Aug;17(4):261–7.
9.
Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights.
Neuroscience
. 2016 Dec;338:183–206.
10.
Xu XS, Etropolski M, Upmalis D, Okamoto A, Lin R, Nandy P. Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR.
Pharm Res
. 2012 Sep;29(9):2555–64.
11.
Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic.
Clin Ther
. 2009 Dec;31(12):2804–18.
12.
Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
J Pharmacol Exp Ther
. 2007 Oct;323(1):265–76.
13.
Tzschentke TM, Jahnel U, Kogel B, Christoph T, Englberger W, De Vry J, et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.
Drugs Today (Barc)
. 2009 Jul;45(7):483–96.
14.
Yang TT, Hung CF, Lee YJ, Su MJ, Wang SJ. Morphine inhibits glutamate exocytosis from rat cerebral cortex nerve terminals (synaptosomes) by reducing Ca2+ influx.
Synapse
. 2004 Feb;51(2):83–90.
15.
Zhu W, Pan ZZ. μ-opioid-mediated inhibition of glutamate synaptic transmission in rat central amygdala neurons.
Neuroscience
. 2005;133(1):97–103.
16.
Llorca-Torralba M, Borges G, Neto F, Mico JA, Berrocoso E. Noradrenergic Locus Coeruleus pathways in pain modulation.
Neuroscience
. 2016 Dec;338:93–113.
17.
Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation.
Neurotherapeutics
. 2009 Oct;6(4):703–12.
18.
Liu MG, Chen J. Roles of the hippocampal formation in pain information processing.
Neurosci Bull
. 2009 Oct;25(5):237–66.
19.
Fasick V, Spengler RN, Samankan S, Nader ND, Ignatowski TA. The hippocampus and TNF: common links between chronic pain and depression.
Neurosci Biobehav Rev
. 2015 Jun;53:139–59.
20.
Rodríguez-Moreno A, Sihra TS. Presynaptic kainate receptor facilitation of glutamate release involves protein kinase A in the rat hippocampus.
J Physiol
. 2004 Jun;557(Pt 3):733–45.
21.
Hsieh TY, Chang Y, Wang SJ. Piperine-mediated suppression of voltage-dependent Ca2+ influx and glutamate release in rat hippocampal nerve terminals involves 5HT1A receptors and G protein βγ activation.
Food Funct
. 2019 May;10(5):2720–8.
22.
Nicholls DG, Sihra TS. Synaptosomes possess an exocytotic pool of glutamate.
Nature
. 1986 Jun;321(6072):772–3.
23.
Nicholls DG. Presynaptic modulation of glutamate release.
Prog Brain Res
. 1998;116:15–22.
24.
Martín ED, Araque A, Buño W. Synaptic regulation of the slow Ca2+-activated K+ current in hippocampal CA1 pyramidal neurons: implication in epileptogenesis.
J Neurophysiol
. 2001 Dec;86(6):2878–86.
25.
Pan R, Tian Y, Gao R, Li H, Zhao X, Barrett JE, et al. Central mechanisms of menthol-induced analgesia.
J Pharmacol Exp Ther
. 2012 Dec;343(3):661–72.
26.
Ma X, Shi TF, Zhang M, Lu XY, Yang CX, Zhu D, et al. Modulatory role of glutamic acid on the electrical activities of pain-related neurons in the hippocampal CA3 -region.
Neurosci Lett
. 2012 Mar;513(1):67–71.
27.
Bouron A. Modulation of spontaneous quantal release of neurotransmitters in the hippocampus.
Prog Neurobiol
. 2001 Apr;63(6):613–35.
28.
Malgaroli A, Tsien RW. Glutamate-induced long-term potentiation of the frequency of miniature synaptic currents in cultured hippocampal neurons.
Nature
. 1992 May;357(6374):134–9.
29.
Ghijsen WE, Leenders AG, Lopes da Silva FH. Regulation of vesicle traffic and neurotransmitter release in isolated nerve terminals.
Neurochem Res
. 2003 Oct;28(10):1443–52.
30.
Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine.
J Pharmacol Exp Ther
. 2008 Jul;326(1):89–99.
31.
Biggs JE, Boakye PA, Ganesan N, Stemkowski PL, Lantero A, Ballanyi K, et al. Analysis of the long-term actions of gabapentin and pregabalin in dorsal root ganglia and substantia gelatinosa.
J Neurophysiol
. 2014 Nov;112(10):2398–412.
32.
Torres-Sanchez S, Borges GD, Mico JA, -Berrocoso E. Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain. 
Neuropharmacology
. 2018 Jun;135:202–10.
33.
Gonçalves L, Friend LV, Dickenson AH. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
Eur J Pharmacol
. 2015 Feb;749:151–60.
34.
Paice JA. Mechanisms and management of neuropathic pain in cancer.
J Support Oncol
. 2003 Jul-Aug;1(2):107–20.
35.
Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
J Pharmacol Exp Ther
. 2011 Apr;337(1):312–20.
36.
Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.
Pain
. 2011 Jan;152(1):131–9.
37.
Benade V, Nirogi R, Bhyrapuneni G, Daripelli S, Ayyanki G, Irappanavar S, et al. Mechanistic evaluation of tapentadol in reducing the pain perception using in-vivo brain and spinal cord microdialysis in rats.
Eur J Pharmacol
. 2017 Aug;809:224–30.
38.
Greco MC, Lisi L, Currò D, Navarra P, Tringali G. Tapentadol inhibits calcitonin gene-related peptide release from rat brainstem in vitro.
Peptides
. 2014 Jun;56:8–13.
39.
Sadeghi M, Tzschentke TM, Christie MJ. μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons.
Br J Pharmacol
. 2015 Jan;172(2):460–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.